共 237 条
[1]
McCombs JS(2004)Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271-287
[2]
Thiebaud P(2010)Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis Osteoporos Int 21 1943-1951
[3]
McLaughlin-Miley C(2012)Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence J Bone Miner Res 27 202-210
[4]
Shi J(2006)Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821-831
[5]
Imaz I(2017)Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients Osteoporos Int 28 559-566
[6]
Zegarra P(2010)Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy J Bone Miner Res 25 72-81
[7]
Gonzalez-Enriquez J(2014)Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT) J Clin Endocrinol Metab 99 2599-2607
[8]
Rubio B(2009)Denosumab in postmenopausal osteoporosis: what the clinician needs to know Ther Adv Musculoskelet Dis 1 13-26
[9]
Alcazar R(2011)Denosumab: a review of its use in the treatment of postmenopausal osteoporosis Drugs Aging 28 63-82
[10]
Amate JM(2011)Effects of denosumab on fracture and bone mineral density by level of kidney function J Bone Miner Res 26 1829-1835